Corticobasal Degeneration News and Research

RSS

Innovative approach to disrupt misfolding of tau proteins in neurodegenerative diseases

A spectrum of neurodegenerative diseases, including frontotemporal dementia (FTD), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are due to the accumulation of abnormal, misfolded tau proteins in the brain.

3 Apr 2024

Redefining the battle against Alzheimer's with tau-focused treatments

Researchers explore the potential of tau-targeting therapies in treating Alzheimer's disease, focusing on immunotherapies and strategies to improve their efficacy. The study dives into the complex biology of tau proteins, their modifications, and how they can be targeted to halt the progression of Alzheimer's.

29 Oct 2023

Possibility of the first fluid biomarker that reflects brain pathology in primary tauopathies

Addressing this gap in research, a recent Nature Medicine study hypothesized that 4R isoform-specific MTBR-tau species accumulate in the patient’s brain of specific subtypes of 4R tauopathies.

28 Nov 2022

New biomarker can help identify people with a primary tauopathy

Zooming in on a single disease and studying it intensely is often the most productive route to finding treatments. But there's no easy way to distinguish among people living with any of the primary tauopathies -; a group of rare brain diseases marked by rapidly worsening problems with thinking and movement -; because the symptoms are too similar.

24 Nov 2022

Researchers uncover new findings about the role of tau in neurodegenerative disease

Utilizing cutting-edge proteomics, researchers at the Buck Institute and elsewhere have mapped the "tau interactome" uncovering new findings about the role of tau in neurodegenerative disease. Publishing in Cell, scientists found that mutant tau impacts the function of mitochondria in human neurons.

20 Jan 2022

Study may lead to new treatments for a wide range of neurological conditions

New research published today sheds important light on how the production of a key protein in the brain is controlled, which could pave the way for new treatments for a wide range of neurological conditions.

19 May 2021

Scientists unlock crucial molecular details regarding tau's activity

Frontotemporal lobar degeneration (FTLD) is a type of dementia that appears earlier in life than Alzheimer's disease (AD).

15 Sep 2020

New test could detect abnormal forms of protein associated with tauopathies

National Institutes of Health scientists have developed an ultrasensitive new test to detect abnormal forms of the protein tau associated with uncommon types of neurodegenerative diseases called tauopathies.

16 Oct 2019

Targeting multiple proteins may be key to treat neurodegenerative disorders

Nearly all major neurodegenerative diseases - from Alzheimer's to Parkinson's - are defined and diagnosed by the presence of one of four proteins that have gone rogue: tau, amyloid-beta, alpha-synuclein, or TDP-43.

6 Jul 2018

Simple blood test may be accurate in differentiating between Parkinson's disease and APDs

A simple blood test may be as accurate as a spinal fluid test when trying to determine whether symptoms are caused by Parkinson's disease or another atypical parkinsonism disorder, according to a new study published in the February 8, 2017, online issue of Neurology, the medical journal of the American Academy of Neurology.

9 Feb 2017

Tau PET imaging in Alzheimer's disease increases opportunities for developing effective drugs

Tau PET is a new and promising imaging method for Alzheimer's disease. A case study from Lund University in Sweden now confirms that tau PET images correspond to a higher degree to actual changes in the brain. According to the researchers behind the study, this increases opportunities for developing effective drugs.

28 Sep 2016

Biopsy of submandibular gland can help identify pathology of Parkinson's disease, dementia with Lewy bodies

Accurate diagnosis of Parkinson's disease, and the related disease "dementia with Lewy bodies," can be difficult in the early stages of both conditions. While brain biopsies can be more accurate, the risk of complications has been considered too high. New research published in the Journal of Parkinson's Disease indicates that a biopsy of the submandibular gland can help identify the same pathology that is seen in the brain, providing some of the increased accuracy of brain biopsy, but not the increased risk.

12 Apr 2016

AbbVie signs exclusive worldwide license agreement with C2N for Alzheimer's disease therapies

AbbVie today announced that it has entered into an exclusive worldwide license agreement with C2N Diagnostics, a privately held protein diagnostic and therapeutic discovery company, to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders.

19 Mar 2015

UC San Diego Health System's Movement Disorder Center joins NPF Center of Excellence network

The Movement Disorder Center at UC San Diego Health System has been designated the 41st Center of Excellence in the National Parkinson Foundation's global network. This designation is the highest recognition offered by NPF to a Parkinson's specialty clinic. It represents the consensus of leaders in the field that the UC San Diego program is among the world's leading centers for Parkinson's research, outreach and care.

27 Feb 2015

Corticobasal Degeneration News and Research

Innovative approach to disrupt misfolding of tau proteins in neurodegenerative diseases

Redefining the battle against Alzheimer's with tau-focused treatments

Possibility of the first fluid biomarker that reflects brain pathology in primary tauopathies

New biomarker can help identify people with a primary tauopathy

Researchers uncover new findings about the role of tau in neurodegenerative disease

Study may lead to new treatments for a wide range of neurological conditions

Scientists unlock crucial molecular details regarding tau's activity

New test could detect abnormal forms of protein associated with tauopathies

Targeting multiple proteins may be key to treat neurodegenerative disorders

Simple blood test may be accurate in differentiating between Parkinson's disease and APDs

Tau PET imaging in Alzheimer's disease increases opportunities for developing effective drugs

Biopsy of submandibular gland can help identify pathology of Parkinson's disease, dementia with Lewy bodies

AbbVie signs exclusive worldwide license agreement with C2N for Alzheimer's disease therapies

UC San Diego Health System's Movement Disorder Center joins NPF Center of Excellence network

Rare Diseases Clinical Research Network awarded $29 million NIH grant

In vivo dopaminergic imaging strongly correlates with brain pathology

Increased brain cell activity boosts protein linked to Alzheimer's disease

Closing in on neurologic biomarker diagnosis

Neurodegenerative disorders are the second-leading cause of early-onset dementia, says report

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News